- WP4 PTJA03 on “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)”
- Final assessment report on MammaPrint® - Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer
Thursday, 15 February 2018
New EUNetHTA reports
Two new reports this month.....